New Catalogue product

APMN, 4-(4’-aminophenyl)-morpholin-3-one, the key intermediate for Rivaroxaban (2.5 mg), a worldwide produced blood thinner, is now part of our catalogue product portfolio. Valsynthese SA has recently launched a strategic investment in hydrogenation, of which APMN is one of the key products.

New Catalogue product

HBTA, Bicyclooctanetetracarboxylic dianhydride, a very promising key intermediate for electronic chemistry, is now part of our catalogue product portfolio. Valsynthese SA has recently launched a strategic investment in hydrogenation. HBTA is one of the key products.